Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Crovalimab for Guillain-Barré Syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Guillain-barré Syndrome

Drugs mentioned

• Crovalimab (crovalimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Guillain-Barré Syndrome | Phase 3 | Status: WITHDRAWN